A groundbreaking study from the University of St Andrews School of Medicine has demonstrated that biomarker-based testing can significantly reduce mortality rates among high-risk individuals for lung cancer. The research, involving 12,000 current and former smokers over five years, revealed that this non-invasive testing method led to a 40% decrease in deaths from lung cancer and other causes. Biomarkers—measurable substances in blood or urine—can detect early bodily changes indicative of diseases like cancer, even before symptoms emerge. This “liquid biopsy” approach enables the identification of individuals at higher risk, facilitating earlier and more effective interventions.
The study’s lead researcher, Professor Frank Sullivan, emphasized the critical role of early detection, stating, “This study shows that earlier diagnosis of lung cancer is now possible.” By focusing on those most likely to develop lung cancer, biomarker testing can enhance existing screening programs, ensuring that resources are directed toward individuals who would benefit most from early diagnosis. This targeted strategy not only improves patient outcomes but also optimizes healthcare efficiency by reducing late-stage cancer treatments, which are often more complex and costly Click for More Details
